Promising Therapeutic Effects of Embryonic Stem Cells-Origin Mesenchymal Stem Cells in Experimental Pulmonary Fibrosis Models: Immunomodulatory and Anti-Apoptotic Mechanisms
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Interstitial lung disease (ILD) involves persistent inflammation and fibrosis, leading to respiratory failure and even death. Adult tissue-derived mesenchymal stem cells (MSCs) show potential in ILD therapeutics but obtaining an adequate quantity of cells for drug application is difficult. Daewoong Pharmaceutical’s MSCs (DW-MSCs) derived from embryonic stem cells sustain a high proliferative capacity following long-term culture and expansion. The aim of this study was to investigate the therapeutic potential of DW-MSCs in experimental mouse models of ILD. DW-MSCs were expanded up to 12 passages for in vivo application in bleomycin-induced pulmonary fibrosis and collagen-induced connective tissue disease-ILD mouse models. We assessed lung inflammation and fibrosis, lung tissue immune cells, fibrosis-related gene/protein expression, apoptosis and mitochondrial function of alveolar epithelial cells, and mitochondrial transfer ability. Intravenous administration of DW-MSCs consistently improved lung fibrosis and reduced inflammatory and fibrotic markers expression in both models across various disease stages. The therapeutic effect of DW-MSCs was comparable to that following daily oral administration of nintedanib or pirfenidone. Mechanistically, DW-MSCs exhibited immunomodulatory effects by reducing the number of B cells during the early phase and increasing the ratio of Tregs to Th17 cells during the late phase of bleomycin-induced pulmonary fibrosis. Furthermore, DW-MSCs exhibited anti-apoptotic effects, increased cell viability, and improved mitochondrial respiration in alveolar epithelial cells by transferring their mitochondria to alveolar epithelial cells. Our findings indicate the strong potential of DW-MSCs in the treatment of ILD owing to their high efficacy and immunomodulatory and anti-apoptotic effects.
Abstract
Interstitial lung disease (ILD) involves persistent inflammation and fibrosis, leading to respiratory failure and even death. Adult tissue-derived mesenchymal stem cells (MSCs) show potential in ILD therapeutics but obtaining an adequate quantity of cells for drug application is difficult. Daewoong Pharmaceutical’s MSCs (DW-MSCs) derived from embryonic stem cells sustain a high proliferative capacity following long-term culture and expansion. The aim of this study was to investigate the therapeutic potential of DW-MSCs in experimental mouse models of ILD. DW-MSCs were expanded up to 12 passages for in vivo application in bleomycin-induced pulmonary fibrosis and collagen-induced connective tissue disease-ILD mouse models. We assessed lung inflammation and fibrosis, lung tissue immune cells, fibrosis-related gene/protein expression, apoptosis and mitochondrial function of alveolar epithelial cells, and mitochondrial transfer ability. Intravenous administration of DW-MSCs consistently improved lung fibrosis and reduced inflammatory and fibrotic markers expression in both models across various disease stages. The therapeutic effect of DW-MSCs was comparable to that following daily oral administration of nintedanib or pirfenidone. Mechanistically, DW-MSCs exhibited immunomodulatory effects by reducing the number of B cells during the early phase and increasing the ratio of Tregs to Th17 cells during the late phase of bleomycin-induced pulmonary fibrosis. Furthermore, DW-MSCs exhibited anti-apoptotic effects, increased cell viability, and improved mitochondrial respiration in alveolar epithelial cells by transferring their mitochondria to alveolar epithelial cells. Our findings indicate the strong potential of DW-MSCs in the treatment of ILD owing to their high efficacy and immunomodulatory and anti-apoptotic effects.
참고문헌 (50)
- Raghu G, "An official ATS", ERS, ALAT clinical practice guideline : treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline, pp.Am J Respir Crit Care Med, 2015[DOI]
- Raghu G, "Diagnosis of idiopathic pulmonary fibrosis. An official ATS", ERS, ALAT clinical practice guideline, pp.Am J Respir Crit Care Med, 2018[DOI]
- du Bois RM, "An earlier and more confident diagnosis of idiopathic pulmonary fibrosis", Eur Respir Rev, 21, pp.141~146 (2012)
- 송진우, "결체조직 질환과 간질성 폐질환", 대한류마티스학회지, 21(6), pp.282~288 (2014), 대한류마티스학회
- Park JH, "Prognosis of fibrotic interstitial pneumonia : idiopathic versus collagen vascular disease-related subtypes", Am J Respir Crit Care Med, 175, pp.705~711 (2007)
- Spagnolo P, "The lung in rheumatoid arthritis : focus on interstitial lung disease", Arthritis Rheumatol, 70, pp.1544~1554 (2018)
- Tsuchiya Y, "Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome", Eur Respir J, 37, pp.1411~1417 (2011)
- Wynn TA, "Integrating mechanisms of pulmonary fibrosis", J Exp Med, 208, pp.1339~1350 (2011)
- Raghu G, "An official ATS", ERS, ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management, pp.Am J Respir Crit Care Med, 2011[DOI]
- Khanna D, "Long-term safety and efficacy of tocilizumab in early systemic sclerosis–interstitial lung disease : openlabel extension of a phase 3 randomized controlled trial", Am J Respir Crit Care Med, 205, pp.674~684 (2022)
- Heukels P, "Inflammation and immunity in IPF pathogenesis and treatment", Respir Med, 147, pp.79~91 (2019)
- Holroyd CR, "The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis", Rheumatology(Oxford), 58, pp.e3~e42 (2019)[DOI]
- 박영재, "Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases", Immune Network, 22(1), pp.1~17 (2022), 대한면역학회[DOI]
- Wollin L, "Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis", Eur Respir J, 45, pp.1434~1445 (2015)
- Richeldi L, "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2071~2082 (2014)
- King TE Jr, "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2083~2092 (2014)
- Aguilar S, "Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis", PLoS One, 4, pp.e8013~ (2009)
- Ortiz LA, "Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects", Proc Natl Acad Sci U S A, 100, pp.8407~8411 (2003)
- Zhao F, "Therapeutic effects of bone marrowderived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats", Transplant Proc, 40, pp.1700~1705 (2008)
- Lee SH, "Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury", fibrosis, 2010, pp.11, 16~
- Mahmoudi T, "Hydrogen peroxide preconditioning promotes protective effects of umbilical cord vein mesenchymal stem cells in experimental pulmonary fibrosis", Adv Pharm Bull, 10, pp.72~80 (2020)
- Liu M, "Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis", Stem Cell Res Ther, 7, pp.63~ (2016)
- Zhao Y, "Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis : a systematic review and implication for clinical application", Stem Cell Res Ther, 12, pp.470~ (2021)
- Li X, "Mesenchymal stem cells in idiopathic pulmonary fibrosis", Oncotarget, 8, pp.102600~102616 (2017)
- Hsu YC, "Mitochondria in mesenchymal stem cell biology and cell therapy : from cellular differentiation to mitochondrial transfer", Semin Cell Dev Biol, 52, pp.119~131 (2016)
- Han S, "Mitochondrial integrated stress response controls lung epithelial cell fate", Nature, 620, pp.890~897 (2023)
- Bernard O, "Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating HIF and ROS hypoxic signaling", Am J Physiol Lung Cell Mol Physiol, 314, pp.L360~L371 (2018)
- Islam MN, "Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury", Nat Med, 18, pp.759~765 (2012)
- Chambers DC, "A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis", Respirology, 19, pp.1013~1018 (2014)
- Glassberg MK, "Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery(AETHER) : a phase I safety clinical trial", Chest, 151, pp.971~981 (2017)
- Averyanov A, "First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline", Stem Cells Transl Med, 9, pp.6~16 (2020)
- Sohni A, "Mesenchymal stem cells migration homing and tracking", Stem Cells Int, 2013, pp.130763~ (2013)
- Ullah I, "Human mesenchymal stem cells-current trends and future prospective", Biosci Rep, 35, pp.e00191~ (2015)
- Kretlow JD, "Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells", BMC Cell Biol, 9, pp.60~ (2008)
- Zhang Y, "Improved cell survival and paracrine capacity of human embryonic stem cell-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension", Cell Transplant, 21, pp.2225~2239 (2012)
- Lian Q, "Derivation of clinically compliant MSCs from CD105+, CD24-differentiated human ESCs", Stem Cells, 25, pp.425~436 (2007)
- Karyana M, "Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection : a randomized, doubleblind, placebo-controlled trial", Stem Cell Res Ther, 13, pp.134~ (2022)
- Hübner RH, "Standardized quantification of pulmonary fibrosis in histological samples", Biotechniques, 44, pp.507~511 (2008)
- Huang P, "N-methyl-D-aspartate receptor blockers attenuate bleomycin-induced pulmonary fibrosis by inhibiting endogenous mesenchymal stem cells senescence", Ann Transl Med, 10, pp.642~ (2022)
- Zhao X, "Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis", Sci Rep, 13, pp.13183~ (2023)
- Wu X, "Human umbilical cord mesenchymal stem cells combined with pirfenidone upregulates the expression of RGS2 in the pulmonary fibrosis in mice", Respir Res, 23, pp.270~ (2022)
- Llontop P, "Airway transplantation of adipose stem cells protects against bleomycin-induced pulmonary fibrosis", J Investig Med, 66, pp.739~746 (2018)
- Chen X, "Human menstrual bloodderived stem cells mitigate bleomycin-induced pulmonary fibrosis through anti-apoptosis and antiinflammatory effects", Stem Cell Res Ther, 11, pp.477~ (2020)
- Li X, "Immunoregulation of bone marrow-derived mesenchymal stem cells on the chronic cigarette smoking-induced lung inflammation in rats", BioMed Res Int, 2015, pp.932923~ (2015)
- Milosavljevic N, "Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells-an experimental study", Transpl Int, 31, pp.102~115 (2018)
- Kurihara K, "Repeated intravenous infusion of mesenchymal stem cells enhances recovery of motor function in a rat model with chronic spinal cord injury", Brain Res, 1817, pp.148484~ (2023)
- Takemura M, "Repeated intravenous infusion of mesenchymal stem cells for enhanced functional recovery in a rat model of chronic cerebral ischemia", J Neurosurg, 137, pp.402~411 (2021)
- Yang CC, "Repeated administration of adiposederived mesenchymal stem cells added on beneficial effects of empagliflozin on protecting renal function in diabetic kidney disease rat", Biomed J, pp.100613~ (2023)
- An L, "Frequent injections of high-dose human umbilical cord mesenchymal stem cells slightly aggravate arthritis and skeletal muscle cachexia in collagen-induced arthritic mice", Exp Ther Med, 22, pp.1272~ (2021)
- Lee HJ, "Chronic inflammation-induced senescence impairs immunomodulatory properties of synovial fluid mesenchymal stem cells in rheumatoid arthritis", Stem Cell Res Ther, 12, pp.502~ (2021)